Annexes

The annexes are available on EMA’s website.

• Annex 1 - Members of the Management Board
• Annex 2 - Members of the Committee for Medicinal Products for Human Use
• Annex 3 - Members of the Pharmacovigilance Risk Assessment Committee
• Annex 4 - Members of the Committee for Medicinal Products for Veterinary Use
• Annex 5 - Members of the Committee on Orphan Medicinal Products
• Annex 6 - Members of the Committee on Herbal Medicinal Products
• Annex 7 - Committee for Advanced Therapies
• Annex 8 - Members of the Paediatric Committee
• Annex 9 - Working parties and working groups
• Annex 10 - CHMP opinions on initial evaluations and extensions of therapeutic indication in 2025
• Annex 11 - Guidelines and concept papers adopted by CHMP
• Annex 12 - CVMP opinions on medicinal products for veterinary use in 2025
• Annex 13 - Guidelines and concept papers adopted by CVMP in 2025
• Annex 14 - COMP opinions on designation of orphan medicinal products in 2025
• Annex 15 - HMPC European Union herbal monographs in 2025
• Annex 16 - PDCO opinions and EMEA decisions on paediatric investigation plans and waivers in 2025
• Annex 17 - Referral procedures overview 2025 – human medicines
• Annex 18 - Arbitrations and referrals in 2025 - veterinary medicines
• Annex 19 - Budget summaries 2024-2025
• Annex 20 - European Medicines Agency establishment plan
• Annex 21 - Litigation activities of EMA in 2025
• Annex 22 - Access to documents requests
• Annex 23 - Clinical Data Publication
• Annex 24 - Publications by Agency staff members and experts in 2025